United Therapeutics Slides as Investors Weigh Insider Selling Against a New Regulatory Milestone

United Therapeutics' nebulized Tyvaso for idiopathic pulmonary fibrosis (IPF) had its sNDA accepted by the FDA. The treatment showed significant efficacy in phase 3 trials, with a 111.8 mL improvement in forced vital capacity over placebo. Review is expected by late April 2027. The company aims for Tyvaso to be the first inhaled anti-fibrotic treatment for IPF if approved.

United Therapeutics (UTHR) announced FDA acceptance of its sNDA for nebulized Tyvaso to treat IPF. The FDA review is expected to conclude in late April 2027. The application is supported by positive Phase 3 study results, showing significant improvements in lung function and quality of life. UTHR stock closed at $512.70, up 0.45%.

United Therapeutics (UTHR) shares are under scrutiny after the FDA accepted its NDA for ralinepag, a treatment for pulmonary arterial hypertension, with a target action date set for June 24, 2027. The company's stock has seen a 1-year return of 67.69% and a 5-year return of 141.31%, but has dipped 9.15% in the past 90 days. Analysts suggest potential undervaluation, with a narrative fair value of $665.23 compared to the recent close of $518.53, citing its pipeline and long-term growth prospects.

The FDA accepted United Therapeutics' NDA for ralinepag, a PAH treatment, with a PDUFA target date of June 24, 2027. The application is based on Phase III trial results showing a 55% reduction in clinical worsening events. If approved, ralinepag would be the first once-daily oral prostacyclin IP receptor agonist for PAH. The company also plans to develop a dry powder inhalation formulation with MannKind.

United Therapeutics (NASDAQ: UTHR) reported Q2 2026 revenues of $783.3 million, down 2% year over year, and net income per diluted share of $7.27 versus $6.41. Tyvaso DPI sales were $326.6 million, while nebulized Tyvaso fell 18% to $126.0 million. Management discussed a path to a $4 billion 2027 revenue run rate amid competitive pressure and upcoming IPF and PAH launches.

United Therapeutics Corporation reported Q2 2026 sales of $783.3M versus $798.6M a year earlier. Net income was $333.0M versus $309.5M. Basic EPS from continuing ops was $7.82 versus $6.86, and diluted EPS was $7.27 versus $6.41. For six months, sales were $1,564.8M versus $1,593.0M; net income $607.9M versus $631.7M.